Depatuxizumab Mafodotin

Preferred Label : Depatuxizumab Mafodotin;

NCIt definition : An epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon intravenous infusion, depatuxizumab mafodotin inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase overexpressed in certain tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.;

UNII : F3R7A4P04N;

CAS number : 1585973-65-4;

Molecule name : ABT-414;

NCI Metathesaurus CUI : CL446449;

Details

Origin ID

C105612;

UMLS CUI

C4477221;

Automatic exact mappings (from CISMeF team)
- depatuxizumab mafodotin [MeSH concept]
Currated CISMeF NLP mapping
- depatuxizumab mafodotin [MeSH Supplementary Concept]
See also inter- (CISMeF)
- ABT-414 [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- ABT-414 [MeSH Supplementary Concept]
- depatuxizumab mafodotin [MeSH Supplementary Concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Epidermal Growth Factor Receptor [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients